ASH 2023 preview – small-molecule duels
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
The upcoming ASH conference will feature rival datasets from inhibitors of Menin, KIT, EZH1/2, BTK, BET, BCR/ABL and more.
Meanwhile, Bristol Myers Squibb hands back two mystery projects.
Assets targeting PSMA and KRAS G12V, plus another gamma-delta Car-T therapy, feature among recently disclosed first-time clinical trial entrants.
But efficacy still needs to go up, as several groups try to combine PD-1 and CTLA-4 using differing approaches.
The presidential session heralds a combo of Padcev and Keytruda as the new front-line bladder cancer standard of care.